Tue, 21 May 2019 11:31:27 GMT
Merck to acquire Peloton in $1.05B cash-deal
On Tuesday, Merck & Co stated it would acquire the cancer drug developer Peloton Therapeutics in a cash deal valued at $1.05B, seeking to receive access to the firm's renal cancer medication candidate PT2977.